Barclays
ORGS

Barclays’s Orgenesis Inc. Common Stock ORGS Stock Holding History

Barclays’s Portfolio ORGS Stock Details ORGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-688
Closed -$4.27K – 5384
2023
Q3 		$4.27K Hold
688
– – ﹤0.01% 4404
2023
Q2 		$9.56K Hold
688
– – ﹤0.01% 4222
2023
Q1 		$8.12K Hold
688
– – ﹤0.01% 4778
2022
Q4 		$13.4K Sell
688
-2
-0.3% -$34 ﹤0.01% 4881
2022
Q3 		$10K Sell
690
-38
-5% -$715 ﹤0.01% 4324
2022
Q2 		$18K Hold
728
– – ﹤0.01% 4451
2022
Q1 		$25K Hold
728
– – ﹤0.01% 4383
2021
Q4 		$21K Sell
728
-247
-25% -$9.66K ﹤0.01% 3948
2021
Q3 		$48K Buy
975
+33
+4% +$1.66K ﹤0.01% 4126
2021
Q2 		$48K Sell
942
-1,361
-59% -$68.5K ﹤0.01% 4153
2021
Q1 		$132K Buy
2,303
+1,275
+124% +$83.1K ﹤0.01% 3888
2020
Q4 		$46K Buy
1,028
+208
+25% +$10K ﹤0.01% 4445
2020
Q3 		$41K Sell
820
-165
-17% -$8.95K ﹤0.01% 4694
2020
Q2 		$61K Buy
+985
New +$59.6K ﹤0.01% 4838
2019
Q4 		– Hold
0
– – – 6909
2019
Q3 		– Hold
0
– – – 7221
2019
Q1 		– Sell
-500
Closed -$23K – 7397
2018
Q4 		$23K Buy
+500
New +$28.7K ﹤0.01% 5843

Other funds holding ORGS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BHB
Bank Hapoalim BM Tel Aviv, Israel $652M AUM 19.01% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $569M AUM 145.59% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Barclays's ORGS Position: Q4 2023 in Review

Barclays sold out of Orgenesis Inc. Common Stock (ORGS) in Q4 2023, closing a stake of 688 shares — an estimated $4.27K sold.

Barclays first reported a position in ORGS in Q4 2018 and held it in 15 quarters. The position peaked at $132K in Q1 2021. 19 funds tracked by Wall St. Rank hold ORGS as of Q4 2023.

  • Barclays reported no remaining Orgenesis Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Barclays sold 688 Orgenesis Inc. Common Stock shares in Q4 2023, an estimated $4.27K.
  • Barclays first reported a position in Orgenesis Inc. Common Stock in Q4 2018 and held it in 15 quarters.
  • Barclays's Orgenesis Inc. Common Stock position peaked at $132K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Orgenesis Inc. Common Stock as of Q4 2023.

Based on Barclays's 13F filing for Q4 2023, filed 15 Feb 2024.